期刊文献+
共找到10篇文章
< 1 >
每页显示 20 50 100
真实世界中银花泌炎灵片治疗急性泌尿系感染的联合用药复杂网络分析 被引量:4
1
作者 孙粼希 张利丹 +3 位作者 谢雁鸣 耿洪娇 刘峘 贾萍萍 《世界中西医结合杂志》 2021年第10期1800-1805,共6页
目的为分析真实世界中银花泌炎灵片治疗急性泌尿系感染时的联合用药药理规律。方法从全国16家三级甲等医院信息系统中提取出银花泌炎灵片治疗急性泌尿系感染的医嘱数据,将联合用药按照药理进行整理合并,标准化后再用Tabu搜索算法分析潜... 目的为分析真实世界中银花泌炎灵片治疗急性泌尿系感染时的联合用药药理规律。方法从全国16家三级甲等医院信息系统中提取出银花泌炎灵片治疗急性泌尿系感染的医嘱数据,将联合用药按照药理进行整理合并,标准化后再用Tabu搜索算法分析潜在规律。结果急性泌尿系感染的好转、治愈人群,应用银花泌炎灵片时常联合使用的中西药理方案有4种:1)联合通淋排石剂、清热利湿剂、抗真菌药、益气剂、解表剂;2)联合尿路解痉药、止血药、补肝肾剂;3)联合清热剂、解热镇痛抗炎药、补益剂、化湿剂、健脾益肾剂;4)联合抗生素类、活血化瘀剂。西药药理选择以抗生素为主,中药药理常见组合为清热剂、化湿剂、补肝肾剂。结论临床治疗急性泌尿系感染多用西药抗生素,中药以清热利湿剂为主,兼补肝肾,与病因、指南推荐、中医淋证基本病机等相契合。体现出中西医联合治疗的优势,可为临床优化处方药理分布提供一定思路参考,同时需根据病情和相关并发症进行个体化用药。 展开更多
关键词 真实世界 银花泌炎灵片 急性泌尿系感染 联合用药 TABU搜索算法
在线阅读 下载PDF
丹参川芎嗪注射液治疗冠心病合并高血压的临床用药特征——一项真实世界研究 被引量:3
2
作者 孙粼希 高阳 +3 位作者 谢雁鸣 张利丹 徐鸿燕 庄严 《海南医学院学报》 CAS 2022年第17期1320-1326,共7页
目的:挖掘应用丹参川芎嗪注射液治疗冠心病合并高血压的特点和用药规律。方法:从全国12家三级甲等医院信息系统中,提取应用丹参川芎嗪注射液治疗冠心病合并高血压患者的医疗数据,标准化后通过Apriori算法建模,并使用Clementine12.0软件... 目的:挖掘应用丹参川芎嗪注射液治疗冠心病合并高血压的特点和用药规律。方法:从全国12家三级甲等医院信息系统中,提取应用丹参川芎嗪注射液治疗冠心病合并高血压患者的医疗数据,标准化后通过Apriori算法建模,并使用Clementine12.0软件进行关联规则分析。结果:1928例患者年龄大多为75~90岁(54.26%),男性多于女性,常合并2型糖尿病、脑梗死等;每次用药剂量多为10 mL以上(52.78%)。临床常联用西药为阿司匹林肠溶片(67.63%)、左卡尼汀注射液(58.77%)、阿托伐他汀钙胶囊(50.93%);常联合的中药为红花黄色素(22.20%)、麝香保心丸(16.55%)、速效救心丸(15.09%);最常联合应用的西药种类为抗凝溶栓及抗血小板药(85.84%)、中药种类是活血化瘀剂(72.98%);联合2种西药最常见的组合为左卡尼汀注射液+阿司匹林肠溶片,支持度41.9%;联合2种中西药物作用最常见的组合是西药·抗心绞痛药+西药·抗凝溶栓及抗血小板药,支持度67.6%。结论:应用丹参川芎嗪注射液的冠心病合并高血压患者以老年男性为主,合并症多;需加强剂量规范;联合用药与指南相契合,有一定规律可循,可提供临床诊治、优化用药线索。 展开更多
关键词 真实世界 丹参川芎嗪注射液 冠心病 高血压 联合用药
在线阅读 下载PDF
Efficacy and Safety of Ginkgo Biloba Tincture(银杏叶酊) Combined with Conventional Medication in the Treatment of Cerebral Infarction: Systematic Review and Meta-analysis 被引量:2
3
作者 赵晓晓 孙粼希 +1 位作者 吕健 谢雁鸣 《World Journal of Integrated Traditional and Western Medicine》 2023年第1期3-14,共12页
Objective:To analyze the efficacy and safety of Ginkgo biloba tincture combined with conventional medication in the treatment of cerebral infarction by systematic evaluation.Methods:Searched the randomized controlled ... Objective:To analyze the efficacy and safety of Ginkgo biloba tincture combined with conventional medication in the treatment of cerebral infarction by systematic evaluation.Methods:Searched the randomized controlled trials of Ginkgo biloba tincture in treating cerebral infarction.English literatures were searched from PubMed,EMbase,Cochrane Library and Web of Science,and Chinese literatures were searched from Chinese Biomedical Literature Database(CBM),China National Knowledge Infrastructure(CNKI),China Science and Technology Journal Database(VIP)and Wanfang Medical Database.At the same time,we searched dissertations,conference papers,and found relevant unpublished research results reports.Literature quality was evaluated using a"bias risk assessment tool"and Meta-analysis using RevMan 5.4 software(from the Cochrane Collaboration).A total of 29 literatures were retrieved,and finally 4 literatures meeting the standards were included.There were 455 samples involved,including 244 cases in the experimental group and 211 cases in the control group.Results:①Effectiveness analysis:The total effective rate of Ginkgo biloba tincture combined with routine treatment was better than that of the control group[RR=1.26,95%CI(1.07,1.47),P=0.005].The hematocrit of Ginkgo biloba tincture combined with conventional treatment was significantly better than that of conventional treatment alone(P<0.05),The neurological deficits of Ginkgo biloba tincture combined with routine therapy was significantly improved(P<0.05).After Ginkgo biloba tincture combined with conventional therapy,the scores of mini-mental state examination(MMSE),activity daily living scale(ADL)and MOSSF-36 quality of life scale were significantly better than those of the control group(P<0.05).②Safety analysis:3 articles reported the safety of medication.There was no obvious change in blood routine,liver and kidney function results and no adverse reactions in the experimental group and the control group.Conclusion:The above results indicated that Ginkgo biloba tincture combined with conventional treatment can improve the total effective rate of patients with cerebral infarction,and it is safe and has no adverse reactions.However,the number of literatures included in this study is small,and the quality of controlled trials is not good.It is still necessary to adopt clinical controlled trials with reasonable design,outcome indicators in line with international social norms and large sample content to further improve the evidence level of clinical research. 展开更多
关键词 Ginkgo biloba tincture Cerebral infarction Systematic evaluation META-ANALYSIS Randomized controlled trial
在线阅读 下载PDF
Systematic Review and Meta-Analysis of Hugan Tablets (护肝片) in the Treatment of Drug-Induced Liver Injury 被引量:1
4
作者 SHA Jing-yu LV Jian +2 位作者 sun Meng-hua XIE Yan-ming sun lin-xi 《World Journal of Integrated Traditional and Western Medicine》 2020年第2期8-25,共18页
Objective:To systematically evaluate the efficacy and safety of Hugan Tablets(护肝片)in the treatment of drug-induced liver injury.Methods:Totally seven Chinese and English databases,including CNKI,Wanfang,VIP,CBM,Pub... Objective:To systematically evaluate the efficacy and safety of Hugan Tablets(护肝片)in the treatment of drug-induced liver injury.Methods:Totally seven Chinese and English databases,including CNKI,Wanfang,VIP,CBM,PubMed,EMbase,Web of Science were searched for randomized controlled trials(RCTs)of Hugan Tablets(护肝片)for the treatment of drug-induced liver injury,which were published from the date of establishment to April 20,2019.The meta-analysis software RevMan 5.3 software and Excel were used to build a database into combine and analyze the studies that met the standards and to draw a forest plot.Results:Forty five RCTs were included with 7478 patients.The quality of included studies was uneven.Meta-analysis showed that the outcome index of liver injury rate was divided into seven subgroups.Hugan Tablets(护肝片)were used in the treatment of anti-tuberculosis drugs was superior to the conventional western medicine treatment group(RR=0.27,95%CI[0.22,0.33],P<0.00001).Which was also better than the without Hugan Tablets(护肝片)treatment group(RR=0.32,95%CI[0.20,0.52],P<0.00001).For the role of drug-induced liver injury in the treatment of type 2 diabetes,the Hugan Tablet+conventional treatment group is better than the conventional treatment group(RR=0.16,95%CI[0.03,0.88],P=0.03).The effect of drug-induced liver injury in the treatment of hypertension was superior to the conventional western medicine treatment group(RR=0.07,95%CI[0.03,0.14],P<0.00001).The effect of drug-induced liver injury during the treatment of hyperlipidemia was not statistically significant(RR=0.57,95%CI[0.33,1.00],P=0.05).There was no statistical difference between the two groups in the effect of drug-induced liver injury during the treatment of coronary heart disease(RR=0.09,95%CI[0.01,1.61],P=0.10).There was no significant difference between the two groups in the treatment of cerebral thrombosis for drug-induced liver injury(RR=0.11,95%CI[0.01,2.01],P=0.14).The effect of anti-hyperthyroidism on liver injury was better than that of conventional western medicine treatment group(RR=0.45,95%CI[0.25,0.82],P=0.009).Outcome index of total effective rate was divided into two subgroups.The effect of drug-induced liver injury caused by the type of drug was not mentioned was superior to the conventional western medicine treatment group(RR=0.78,95%CI[0.70,0.88],P<0.0001).There was no significant difference between the two groups in the liver injury caused by antipsychotic drugs(RR=0.97,95%CI[0.81,1.16],P=0.72).Conclusion:When used in the treatment of tuberculosis and psychiatric drug treatment,combineduse of Hugan Tablets(护肝片)can significantly reduce the incidence of drug-induced liver damage,and can significantly improve clinical symptoms caused by liver damage.In the treatment of hypertension,the addition of Hugan Tablets(护肝片)can significantly reduce the incidence of drug-induced liver injury,improving the safety of medication.In the treatment of drug-induced liver injury caused by which drug is not mentioned,Hugan Tablet has a therapeutic effect.Slight adverse reactions were reported,including rash,headache,palpitations,hypoglycemia,flushing,fatigue,nausea,bowel sounds,flatulence,diarrhea,and gastrointestinal discomfort.All studies reported minor adverse reactions that were well tolerated by patients and recovered without treatment after discontinuation.Oral administration of Hugan Tablets(护肝片)has positive effects on druginduced liver injury,but this conclusion still needs further evidences delete.It is necessary to adopt a larger sample,more design,and accord with the international standards to improve the quality of evidence. 展开更多
关键词 Hugan Tablets(护肝片) Drug-induced liver injury META-ANALYSIS Systematic review Randomized controlled trial
在线阅读 下载PDF
Systematic Review and Meta-Analysis of Fuke Qianjin Tablets(妇科千金片)in the Treatment of Chronic Pelvic Inflammation 被引量:1
5
作者 GE Xiao-chen LV Jian +3 位作者 sun Meng-hua XIE Yan-ming sun lin-xi ZHANG Li-dan 《World Journal of Integrated Traditional and Western Medicine》 2020年第3期23-41,共19页
Objective:To systematically evaluate the efficacy and safety of Fuke Qianjin Tablets(妇科千金片)in the treatment of chronic pelvic inflammation.Methods:A systematically and comprehensively search was conducted in 4 Ch... Objective:To systematically evaluate the efficacy and safety of Fuke Qianjin Tablets(妇科千金片)in the treatment of chronic pelvic inflammation.Methods:A systematically and comprehensively search was conducted in 4 Chinese databases of CNKI,VIP,Wan Fang and CBM and the foreign language databases of Pubmed,EMbase and The Cochrane Library.The retrieval time was from database establishment to March 2019.The randomized controlled trials of Fuke Qianjin Tablets(妇科千金片)in the treatment of chronic pelvic inflammation were selected according to the predetermined criteria.The quality of the included study was evaluated by Cochrane collaborative network bias risk evaluation tool,and the meta-analysis was performed by Rev Man5.3 software.Results:A total of 1009 related literatures were searched.After initial screening and strict evaluation,55 studies were included,with a total sample size of 6826 cases,including 3416 cases in the experiment group and 3410 cases in the control group.The results of meta-analysis showed that the total effective rate of Fuke Qianjin Tablets(妇科千金片)combined with antibiotics in the treatment of chronic pelvic inflammation was better than that of antibiotics alone(RR=1.20,95%CI[1.17,1.22],P<0.00001).Fuke Qianjin Tablets(妇科千金片)combined with antibiotics was better than that of antibiotics alone in the improvement of abdominal pain symptoms(RR=1.40,95%CI[1.04,1.88],P<0.00001),leukorrhea abnormality(RR=1.38,95%CI[1.16,1.65],P<0.0004).In terms of safety,Fuke Qianjin Tablets(妇科千金片)combined with antibiotics could reduce the incidence of adverse reactions(RR=0.67,95%CI[0.48,0.93],P<0.02).The main adverse reactions were nausea and vomiting,bitterness and astringency in the mouth,rash and so on.All of them could be tolerated and the symptoms could disappear in the short term,and had no effect on the treatment.Conclusion:Fuke Qianjin Tablets(妇科千金片)combined with antibiotics in the treatment of chronic pelvic inflammation can improve the total effective rate,relieve abdominal pain and abnormal leukorrhea and other clinical discomfort symptoms,improve the quality of life of patients to a certain extent,and no serious adverse reactions are found.Due to the limitation of the quality and quantity of the included literature,the above conclusions need to be further studied and verified by high-quality research. 展开更多
关键词 Fuke Qianjin Tablets(妇科千金片) Chronic pelvic inflammation Systematic evaluation Randomized controlled trial META-ANALYSIS
在线阅读 下载PDF
Clinical characteristics of Danshen Ligustrazine injection in the treatment of coronary heart disease with hypertension-A real world study
6
作者 sun lin-xi Gao Yang +3 位作者 XIE Yan-ming Zhang Li-dan XU Hong-yan ZHUANG Yan 《Journal of Hainan Medical University》 2022年第17期39-46,共8页
Objective:To explore the characteristics and rules of Danshen Ligustrazine Injection in the treatment of coronary heart disease with hypertension.Methods:From the information systems of 12 tertiary tier-one hospitals ... Objective:To explore the characteristics and rules of Danshen Ligustrazine Injection in the treatment of coronary heart disease with hypertension.Methods:From the information systems of 12 tertiary tier-one hospitals across the country,we extracted the medical data of the application of Danshen Ligustrazine Injection in the treatment of patients with coronary heart disease and hypertension.After normalization,the model was established by Apriori algorithm,and the association rules were analyzed by Clementine 12.0 software.Results:Most of the 1928 patients were between 75 and 90 years old(54.26%).There were more males than females,most with type 2 diabetes,cerebral infarction,etc.Each dose was more than 10 mL(52.78%).Aspirin enteric-coated tablets(67.63%),L-carnitine injection(58.77%),and atorvastatin calcium capsules(50.93%)were often used in combination with safflower yellow pigment(22.20%),Shexiang Baoxin Pill(16.55%),Suxiao Jiuxin Pill(15.09%);the most commonly used combination of western medicine was anticoagulant thrombolytic and antiplatelet drugs(85.84%),and the type of Chinese medicine was Huoxuehuayu(72.98%);The most common combination of two western medicines was L-carnitine injection+aspirin enteric-coated tablets,with a support of 41.9%;The most common combination of two Chinese and western medicines is western medicine·anti-anginal medicine+western medicine·anticoagulant thrombolytic and antiplatelet drugs with a support of 67.6%.Conclusion:Danshen Ligustrazine injection is mainly used in elderly patients with coronary heart disease and hypertension,with many comorbidities.The dosage standard needs to be optimized.The combination of drugs and guidelines should coordinate with each other,which provide clues for clinical diagnosis and treatment and optimization of medication. 展开更多
关键词 Real world Danshen Ligustrazine Injection Coronary heart disease HYPERTENSION Combination medication
在线阅读 下载PDF
真实世界研究中16856例应用速效救心丸的老年患者临床特征及联合用药规律 被引量:10
7
作者 孙粼希 黎元元 +2 位作者 谢雁鸣 王欢 庄严 《中国中药杂志》 CAS CSCD 北大核心 2020年第10期2335-2342,共8页
自2001-2015年采集37家三级甲等医院信息系统中16 856例应用速效救心丸,且65岁以上的老年患者医疗数据,规范后分析发现:16 856例老年患者平均年龄72.48岁,入院科室主要为心内科(19.30%)和老年病科(9.77%)。入院病情一般者占61.96%,平均... 自2001-2015年采集37家三级甲等医院信息系统中16 856例应用速效救心丸,且65岁以上的老年患者医疗数据,规范后分析发现:16 856例老年患者平均年龄72.48岁,入院科室主要为心内科(19.30%)和老年病科(9.77%)。入院病情一般者占61.96%,平均住院时间16.16 d;患者主要西医诊断为冠心病,占研究中总诊断数的47.97%,主要中医证候为气虚血瘀证,占5.86%;临床常联合的西药为硝酸异山梨酯(61.15%)、阿司匹林肠溶片(50.77%)、肝素(36.88%),常联合的中药为复方丹参滴丸/片(19.13%)、血塞通胶囊/注射液(15.01%)、麝香保心丸(12.29%);常联合应用的西药种类为血管扩张药(78.39%)、中药种类是活血化瘀剂(82.04%),常用西药组合为阿司匹林肠溶片+硝酸异山梨酯。该研究意在挖掘有价值的临床特点及联合用药方案线索,发现速效救心丸应用基本符合说明书,合乎老年人共病众多、兼症繁杂的特点;联合用药与适应症--冠心病指南相契合,有一定规律可循,对拓展速效救心丸临床应用的认知度,提供临床诊治思路。 展开更多
关键词 速效救心丸 老年患者 真实世界研究 医院信息系统(HIS) 临床特征 联合用药
原文传递
真实世界中丹参川芎嗪注射液治疗脑梗死人群的临床用药特征研究 被引量:16
8
作者 郭晓晨 高阳 +3 位作者 谢雁鸣 孙粼希 徐鸿燕 庄严 《中国中药杂志》 CAS CSCD 北大核心 2020年第14期3307-3315,共9页
该研究对使用丹参川芎嗪注射液治疗脑梗死人群的临床特征和联合用药规律进行分析。选取全国20家三级甲等医院HIS数据库中使用丹参川芎嗪注射液的2857例脑梗死患者的住院信息,采用描述分析、Apriori算法建立模型,探究丹参川芎嗪注射液治... 该研究对使用丹参川芎嗪注射液治疗脑梗死人群的临床特征和联合用药规律进行分析。选取全国20家三级甲等医院HIS数据库中使用丹参川芎嗪注射液的2857例脑梗死患者的住院信息,采用描述分析、Apriori算法建立模型,探究丹参川芎嗪注射液治疗脑梗死的临床特征及联合用药规律。结果显示,使用丹参川芎嗪注射液的脑梗死患者中,65岁以上患者共1727例,占69.61%,男性1610例,占63.59%。治疗上与降脂药、抗凝溶栓及抗血小板药、脑代谢功能促进剂、血管扩张药等西药,以及中药活血化瘀剂、清热剂、祛痰剂等联合使用较为常见。与丹参川芎嗪注射液联合使用频数最高的西药是阿司匹林肠溶片(1528例,53.48%),中药是醒脑静注射液(378例,13.23%);其中与丹参川芎嗪注射液最常用的西药合并用药类别是抗凝溶栓及抗血小板药,使用率达83.48%,最常用的中药合并用药类别是活血化瘀剂,使用率达63.49%。为了更深入地探索丹参川芎嗪注射液的合并用药规律,对使用丹参川芎嗪注射液的脑梗死患者合并药物进行关联分析。临床联合2种西药时,最常联用阿托伐他汀钙胶囊+脑蛋白水解物注射液组合,支持度27.10%;联合3种西药时,最常联用硫酸氢氯吡格雷片+阿托伐他汀钙胶囊+脑蛋白水解物注射液组合,支持度15.90%。结果表明,使用丹参川芎嗪注射液的脑梗死患者以老年男性为主,常合并高血压病、冠心病、糖尿病等基础疾病;丹参川芎嗪注射液的临床应用与指南基本相符,其在治疗脑梗死时常与西药抗凝溶栓及抗血小板药、中药活血化瘀剂等药理作用相似的药物联合使用,且对合并有其他疾病的脑梗死患者有辅助治疗作用,为临床用药提供指导。 展开更多
关键词 真实世界 脑梗死 丹参川芎嗪注射液 用药特征 关联规则
原文传递
基于真实世界12554例刺五加注射液用药患者临床特征及联合用药分析 被引量:4
9
作者 孙粼希 谢雁鸣 +2 位作者 刘峘 黎元元 庄严 《中国中药杂志》 CAS CSCD 北大核心 2020年第15期3505-3510,共6页
该研究为挖掘使用刺五加注射液患者的真实世界临床特征和联合用药规律,从全国共24家三级甲等医院信息系统中,提取12 554例刺五加注射液用药患者的医疗数据,进行规范化分析。中老年患者使用居多,心血管内科(22.50%)和神经内科(17.92%)是... 该研究为挖掘使用刺五加注射液患者的真实世界临床特征和联合用药规律,从全国共24家三级甲等医院信息系统中,提取12 554例刺五加注射液用药患者的医疗数据,进行规范化分析。中老年患者使用居多,心血管内科(22.50%)和神经内科(17.92%)是主要住院科室;2008年以前单次超剂量使用者占93.77%,2011年后仅2.07%;疗程多在8~14 d(32.98%)。西医诊断前3位依次是高血压病(11.78%)、脑梗死(9.47%)、冠心病(8.15%),最常见的中医证候为肝肾亏虚证(18.59%)。临床最常联用的西药为乙酰水杨酸(51.07%)、中药为丹参注射液(9.67%),最常联合应用西药类别是钙通道阻断药(46.88%)、中药类别为祛瘀剂(93.21%),支持度最高的联合用药组合为单硝酸异山梨酯+乙酰水杨酸;出院治愈好转率高(96.81%)。结果表明刺五加注射液联合用药有一定规律可循,在抗凝活血基础上兼顾基础并发疾病,且有扶正调神作用。此结果可拓展对刺五加注射液认识的广度,为临床优化治疗方案提供较详实的真实世界依据和借鉴。 展开更多
关键词 刺五加注射液 真实世界 医院信息系统(HIS) 临床特征 联合用药
原文传递
真实世界醒脑静注射液治疗脑出血临床应用特征分析 被引量:12
10
作者 石丹丹 吕健 +3 位作者 谢雁鸣 孙粼希 刘美霞 张敏 《中国中药杂志》 CAS CSCD 北大核心 2020年第15期3511-3517,共7页
该文基于真实世界研究,探索使用醒脑静注射液脑出血患者人群特征及临床用药特征。采用Apriori算法建立模型,使用Clementine 12.0对全国33家三级甲等医院信息系统数据库的8 369例使用醒脑静注射液的脑出血患者一般信息及用药信息进行分... 该文基于真实世界研究,探索使用醒脑静注射液脑出血患者人群特征及临床用药特征。采用Apriori算法建立模型,使用Clementine 12.0对全国33家三级甲等医院信息系统数据库的8 369例使用醒脑静注射液的脑出血患者一般信息及用药信息进行分析。结果显示,使用醒脑静注射液的8 369例脑出血患者中,年龄中位数59岁,男-女1.74∶1,职业以体力劳动者最多(31.26%),多于冬季入院(27.46%),节气多在寒露(5.1%),入院病情以一般者居多(50.94%),就诊时首选神经外科(48.82%),住院天数多在15~28 d(29.03%),有42.47%患者住院费用在10 000~50 000元;醒脑静注射液单次给药剂量以10~20 mL最多(46.03%);用药疗程大多在3 d及以下(68.60%);合并1种西药用药频数最高的为利多卡因(5.05%),合并1种中药用药常为化瘀通脉剂(10.73%)。1种中药合并1种西药频次最高的是化瘀通脉剂+地塞米松(8.08%);联合2种西药频数最高的是奥美拉唑+地塞米松(5.07%);联合3种西药频数最高的为奥美拉唑+地塞米松+利多卡因(3.35%);在用药10~20 mL,用药天数>15 d时,治愈和好转的患者最多(44.78%,45.85%)。结果表明,使用醒脑静注射液治疗脑出血患者以中老年居多且男性多于女性,多于冬春时节发病,常与糖皮质激素、质子泵抑制剂、心血管药物等联用预防脑出血并发症,临床用药符合脑出血治疗指南,部分患者存在超疗程使用情况,可为临床医师治疗时提供参考。 展开更多
关键词 醒脑静注射液 脑出血 真实世界 医院信息系统 病症特征 用药特征
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部